Navigation Links
Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer

VALENCIA, Calif., April 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that Matthew J. Pfeffer will join the company as Corporate Vice President and Chief Financial Officer, effective April 21, 2008. Mr. Pfeffer will report to Hakan Edstrom, President and Chief Operating Officer, and will serve on MannKind's executive leadership team. Mr. Pfeffer's appointment follows the previously announced retirement of Dick Anderson, who has now transitioned to the role of Corporate Vice President -- Office of the Chairman.

Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine-year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer is a member of the board of directors of Genelabs Technologies, Inc. He also serves on boards and advisory committees of Financial Executives International, the Biotechnology Industry Organization and the American Institute of Certified Public Accountants. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.

"Matt is a seasoned and knowledgeable Chief Financial Officer with over 25 years of demonstrated financial management experience. We know that he will play a significant role on MannKind's executive leadership team as we continue to develop our pipeline of diabetes and oncology products," said Hakan Edstrom. "We are extremely pleased to have him on the team."

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
2. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
5. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
6. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
7. Cord Blood America Says Pennsylvania Joins New York and California in Establishing Educational Programs on the Benefits of Umbilical Cord Blood Storage
8. Holly Smith Joins Profect as Director of Clinical Imaging Services
9. Ex-Allergan Vice President Joins Kalologie Skincare Board of Directors
10. Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics
11. Louis Drapeau Joins Bionovos Board of Directors
Post Your Comments:
(Date:11/24/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today announced ... chief executive officer, will present at the 27 th ... New York City . The presentation will be webcast ... 9:30 a.m. EST. and go to ... 15 minutes prior to the presentation to allow for any ...
(Date:11/24/2015)... 24, 2015 According to two new studies, fewer ... is something that many doctors, scientists, and public health experts ... with fewer PSA tests being done, will there be more ... Dr. David Samadi, "Despite the efforts made in regards ... second leading cancer cause of death in men, killing approximately ...
(Date:11/23/2015)... 23, 2015 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the second quarter ... 30, 2015. --> --> ... Revenues for the second quarter of fiscal 2016 increased ...
(Date:11/23/2015)... GENEVA , November 23, 2015 ... to develop daclatasvir for 112 ... countries   --> --> ... licence for a hepatitis C medicine, signing an agreement with ... proven to help cure multiple genotypes of the HCV virus. ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):